Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 76 trials

Late-Stage Pipeline

57%

43 trials in Phase 3/4

Results Transparency

300%

6 of 2 completed trials have results

Key Signals

40 recruiting6 with results

Enrollment reporting

Analytics

Phase 4

30(42.3%)

Phase 3

13(18.3%)

Phase 2

13(18.3%)

Phase 2/3

6(8.5%)

N/A

3(4.2%)

Phase 1

3(4.2%)

Phase 1/2

3(4.2%)

71Total

Phase 4(30)

Phase 3(13)

Phase 2(13)

Phase 2/3(6)

+3 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (76)

Showing 20 of 76 trials

NCT05926063Phase 4Completed

Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia

Role: lead

NCT07405671Phase 4Recruiting

Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation

Role: lead

NCT07876648Not ApplicableRecruiting

Prospective Trial of [18F]AlF-FAPI-74 for PET Imaging of Fibroblast Activation Protein in Patients With Endometriosis

Role: lead

NCT07870538Phase 4Recruiting

A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum

Role: lead

NCT05569772Phase 3Recruiting

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

Role: lead

NCT07676331Phase 2Not Yet Recruiting

Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial

Role: lead

NCT07570472Phase 2Recruiting

The Effect of CBD on Sleep Quality Following Late Evening Exercise

Role: lead

NCT05169593Phase 4Recruiting

Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy

Role: lead

NCT06916390Phase 4Recruiting

GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis

Role: lead

NCT06767631Not ApplicableRecruiting

Pilot Study on Muscle, Tendon, and Neural Changes Post-Botulinum Toxin Injections in Post-stroke Spastic Equinovarus

Role: lead

NCT07535554Phase 2/3Recruiting

The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.

Role: lead

NCT06365788Phase 2Recruiting

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

Role: lead

NCT07477444Phase 1/2Not Yet Recruiting

Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer

Role: lead

NCT06830239Phase 2Recruiting

Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer

Role: lead

NCT07380204Not ApplicableRecruiting

Quantification of Hsp90 in the Human Brain

Role: lead

NCT06962137Phase 2Recruiting

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

Role: lead

NCT07104487Phase 2Recruiting

[18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease

Role: lead

NCT06482671Phase 3Recruiting

Primary Care dySpEpsia rikkuNshiTo

Role: lead

NCT06003283Phase 4Recruiting

Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis

Role: lead

NCT03642665Phase 4Completed

Natural Versus Artificial Cycle for Frozen-Thawed Embryo Transfer

Role: lead